The Efficacy and Controversy of Octreotide and Somatostatin Analogues in the Treatment of Chronic Pancreatitis: A Review

Abstract

Chronic pancreatitis (CP) is a progressive fibro-inflammatory disease of the pancreas that causes chronic pain, maldigestion, endocrine insufficiency and frequent local complications such as pseudocysts and fistulae. Octreotide (a synthetic somatostatin analogue) and somatostatin reduce pancreatic exocrine secretion through somatostatin receptor–mediated mechanisms, and have been evaluated for symptom control, complication prevention and perioperative use in pancreatic surgery. Available data show biologically plausible effects (reduced pancreatic enzyme output and modulation of inflammation), clearer benefit in some acute and perioperative contexts (reduced postoperative pancreatic fistula in several trials), but heterogeneous and inconsistent results in chronic pancreatitis for long-term pain control and complication prevention

Keywords

Chronic pancreatitis; Octreotide; Somatostatin; Pain management; Pancreatic secretion; Pseudocyst; Pancreatic fistula

Introduction

Chronic pancreatitis (CP) produces irreversible structural damage to the pancreas, progressive fibrosis, loss of exocrine and endocrine function, and chronic abdominal pain that substantially reduces quality of life. Concerns about sphincter of Oddi contraction, tachyphylaxis with prolonged use, and variable study design limit broad recommendations. Further large, well-designed RCTs are required to identify patient subgroups most likely to benefit, optimal dosing/duration strategies, and combination therapies. [1–6].  pathophysiology is multifactorial (alcohol, genetic predisposition, ductal obstruction, metabolic causes, autoimmune) and includes recurring injury–repair cycles, fibrosis, neural remodelling and central sensitization that complicate analgesic management. Therapeutic goals are pain control, preservation of nutrition and function, management of complications (pseudocysts, fistulae, biliary obstruction) and improving quality of life. Pharmacologic inhibition of exocrine secretion (pancreatic “rest”) remains an attractive strategy because it targets a proximal driver of autodigestion and local inflammation. [7–10]

 

Literature Search Strategy :

This review was conducted using a structured literature search to identify relevant studies evaluating the role of somatostatin and its analogues, particularly octreotide, in the management of chronic pancreatitis.

Electronic databases including PubMed, Cochrane Library, and Google Scholar were searched for articles published between 1990 and 2024. The following keywords and combinations were used:

• Chronic pancreatitis
• Octreotide
• Somatostatin analogues
• Pancreatic fistula
• Pain management in chronic pancreatitis
• Somatostatin in pancreatic surgery

Boolean operators such as AND and OR were applied to refine the search. Only peer-reviewed articles, randomized controlled trials, systematic reviews, and observational studies published in English were included.

Studies focusing on acute pancreatitis without relevance to chronic disease, animal studies without translational significance, and articles lacking sufficient methodological quality were excluded.

Pharmacology and Mechanism of Action :

Somatostatin and synthetic analogues (e.g., octreotide, larazotide) bind to somatostatin receptor subtypes (SSTR1–5) on pancreatic acinar and ductal cells and neuroendocrine cells in the gut. Receptor activation inhibits intracellular cAMP and Ca²? signalling pathways, suppressing exocytosis of zymogen granules and release of gastrointestinal hormones (CCK, gastrin, VIP), thereby reducing pancreatic enzyme secretion (amylase, lipase, proteases). Clinically measurable outcomes include reductions in stimulated pancreatic secretory markers (e.g., duodenal bicarbonate, faecal/serum enzyme proxies). Somatostatin analogues also influence splanchnic blood flow, microcirculation and inflammatory mediators, which may further mitigate injury in acute settings.  The schematic illustrates the two opposing pharmacological effects of somatostatin analogues:

Beneficial Effects :

• Inhibition of pancreatic exocrine secretion
• Reduction of pancreatic enzyme output
• Decreased pancreatic inflammation
• Possible reduction of postoperative pancreatic fistula

Potential Adverse Effects :

• Increased sphincter of Oddi tone
• Increased ductal pressure
• Possible worsening of pancreatic pain in susceptible patients

This dual mechanism highlights the therapeutic benefit–risk balance when using somatostatin analogues in chronic pancreatitis. However, somatostatin analogues can increase sphincter of Oddi tone and basal pressure — a pharmacodynamic effect with potential to increase ductal outflow resistance and ductal pressure in susceptible patients, possibly worsening pain or causing obstruction-related complications. Tachyphylaxis (reduction in pharmacologic effect) with continuous administration over days has been reported and may limit long-term utility. [11–16]. 

Evidence for Symptom (Pain) Control in Chronic Pancreatitis

Clinical trials and observational data :

Clinical studies investigating octreotide in chronic pancreatitis have reported mixed results. Some randomized controlled trials demonstrate moderate reductions in pain intensity and analgesic requirements in selected patients receiving longer treatment courses. In contrast, short?term therapy often fails to produce significant clinical improvement despite biochemical suppression of pancreatic secretion. These findings suggest that mechanisms beyond enzyme secretion, such as neural sensitization and structural pancreatic damage, play important roles in chronic pancreatitis pain.     

• Several randomized and controlled trials have examined octreotide/somatostatin in CP pain. Results are mixed: some studies report moderate pain reduction and decreased analgesic use with prolonged regimens (weeks), whereas short courses (<7 days) generally fail to show meaningful clinical benefit despite demonstrable biochemical suppression of secretion. [17–20]. 
• A double-blind crossover trial in patients with chronic alcoholic pancreatitis demonstrated that strong short-term suppression of secretion (3 days) did not translate into significant reductions in pain scores or analgesic consumption, suggesting that factors beyond acinar secretion (e.g., neural sensitization) are major pain drivers. [21]. 
• Tachyphylaxis: some work suggests the inhibitory effect on secretion may attenuate after ~7 days of continuous exposure, which limits sustained symptomatic control unless dosing strategies are adapted. [22]

Interpretation :

Overall, suppression of exocrine secretion with somatostatin analogues can produce biochemical improvement and occasional symptomatic benefit for selected patients, particularly with longer courses, but evidence is inconsistent. Patient selection (those with active secretory-driven ductal hypertension vs. those with neuropathic pain) appears crucial.

 

Prevention and Management of Complications (Pseudocysts, Fistulae, Post-operative Leaks) :

Perioperative prophylaxis and pancreatic surgery :

• Several randomized controlled trials and meta-analyses examined perioperative octreotide to prevent postoperative pancreatic fistula and related complications after pancreatic resection. Early landmark trials (including Montori et al., Buchler et al., Peder Zoli et al.) reported reduced postoperative fistula rates and some reduction in overall complications with perioperative octreotide. [22, 23–25]. 
• Subsequent systematic reviews/meta-analyses show heterogeneity: some pooled analyses support reduction in fistula/complication rates and shorter hospital stay, whereas others find no clear mortality benefit and emphasize trial quality and heterogeneity. Contemporary Cochrane/systematic reviews conclude somatostatin analogues may reduce perioperative complication rates in selected settings (particularly high-risk anastomoses), but definitive universal recommendations remain cautious pending larger low-bias trials. [3, 24]. 

• Pseudocysts and pancreatic fistulae outside surgery
• Case series and small controlled studies suggest somatostatin analogues may accelerate pseudocyst regression and assist in closing persistent pancreatic fistulae by reducing exocrine flow, but large, high-quality randomized data are limited. Where endoscopic or surgical drainage is possible, somatostatin analogues may be used adjunctively. Evidence remains largely observational and heterogeneous. [26–29

 

 

Interpretation :

Perioperative use in pancreatic surgery has the strongest and most reproducible evidence for reducing certain complications (e.g., fistula) in selected contexts. For non-surgical CP complications (pseudocyst, spontaneous fistula), evidence is weaker and mostly from small series; octreotide/somatostatin may help some patients but cannot replace drainage when indicated.

Acute vs. Chronic Pancreatitis: Where Benefits Are Clearer :

Most consistent beneficial data for somatostatin analogues exist in acute severe pancreatitis (APS) models and some clinical settings, where enzyme suppression and modulation of inflammatory cascades can mitigate systemic inflammatory response and multi-organ dysfunction. Meta-analyses indicate benefit in selected AP outcomes, and experimental models support anti-inflammatory and microcirculatory protective effects. By contrast, chronic disease involves fixed structural changes (fibrosis, ductal strictures) and neuropathic mechanisms less amenable to secretion suppression alone. [30–33].  ?

Safety, Adverse Effects and Limitations :

• Common side effects: gastrointestinal upset (nausea, diarrhea, bloating), gallbladder stasis/gallstones with long-term use, and injection-site reactions for subcutaneous depot formulations.³⁴
• Sphincter of Oddi effects: octreotide increases basal sphincter pressure and contraction frequency in manometry studies — a mechanistic concern because increased sphincter tone may raise ductal pressure and worsen pain or obstructive complications in susceptible patients. Careful clinical assessment for Sphincter of Oddi Dysfunction (SOD) or fixed obstructions is indicated before or during therapy. [11, 12]. 
• Tachyphylaxis: attenuation of secretory suppression with prolonged continuous exposure limits long-term effectiveness; intermittent dosing, higher doses, or depot formulations have been used but evidence is limited. [22]. 

Practical Considerations and Clinical Recommendations :

1. Role as an adjunct rather than first-line — Somatostatin analogues should be considered adjunctive for CP: i.e., for refractory pain where secretion-driven ductal hypertension is suspected, for persistent pancreatic fistulae as part of a multimodal plan, or perioperatively in patients at higher risk for pancreatic fistula after resection. [3, 23, 26].  ?
2. Patient selection — Best candidates: patients with demonstrable ongoing exocrine hypersecretion, ductal hypertension amenable to decompression (or as a temporizing measure), or those with postoperative high-risk anastomoses. Avoid in patients with known downstream obstruction at the papilla unless decompressed.
3. Dosing and duration — Trials vary widely. Short courses (<7 days) often fail to relieve pain; some benefit has been seen with prolonged therapy (weeks). Perioperative regimens typically cover immediate postoperative days (e.g., 5–7 days) and show reduction in fistula rates in several trials. Monitor for tachyphylaxis in longer courses. [22–24].  ?
4. Monitoring and safety — Monitor for GI adverse effects, gallbladder dysfunction, glycemic changes (somatostatin analogues can affect insulin/glucagon), and signs of obstructive pancreatopathy. Consider manometry or imaging if symptoms worsen. [11, 34].  ?
5. Combination therapy — Combining with other agents (e.g., protease inhibitors such as ulinastatin) has shown promise in acute settings and is used in some regions, but evidence in chronic pancreatitis is limited and inconsistent. [12, 30].  ?

Knowledge Gaps and Future Research Directions :

• High-quality, long-term RCTs in CP comparing optimized octreotide/analogue dosing vs. placebo or standard care, with stratification by disease phenotype (obstructive vs. neuropathic pain, etiology), are lacking.
• Biomarker-guided selection: tests that identify secretion-driven disease (e.g., stimulated pancreatic output, ductal pressure measures) might help select patients who will benefit.
• Pharmacologic innovation: analogues with sustained receptor activity but minimal sphincter of Oddi stimulation could improve the benefit/risk ratio.
• Combination strategies: randomized trials testing somatostatin analogues + endoscopic decompression vs. endoscopy alone (or combined with protease inhibitors) would clarify additive benefit.
• Mechanistic studies: translational work on neuropathic mechanisms and how secretion suppression interacts with neural remodelling is warranted to tailor multimodal pain strategies.

CONCLUSION

Somatostatin and its analogues remain biologically plausible therapeutic options in chronic pancreatitis due to their ability to suppress pancreatic exocrine secretion and modulate inflammatory processes. Their most consistent clinical role appears in perioperative management to reduce pancreatic fistula risk after surgery and in selected refractory cases of chronic pancreatitis. However, evidence supporting routine long?term use for chronic pancreatitis pain remains inconsistent. High?quality, long?term randomized controlled trials focused on disease phenotype and optimized dosing strategies are needed to clarify their role in clinical practice.

Octreotide and somatostatin analogues retain a biologically plausible role in CP through potent inhibition of pancreatic enzyme secretion and modulation of inflammatory pathways. The clearest clinical utility presently lies in perioperative prophylaxis for pancreatic surgery (reduction in postoperative fistula in selected trials) and in selected refractory cases for symptom control or complication management. However, the evidence for routine long-term use in chronic pancreatitis pain management is inconsistent due to disease heterogeneity, persistent neuropathic mechanisms, potential sphincter of Oddi adverse effects, and tachyphylaxis with prolonged therapy. Future high-quality, phenotype-stratified randomized trials and improved analogues/delivery systems are needed to define optimal use. Despite biologically plausible mechanisms, high-quality long-term randomized controlled trials in chronic pancreatitis remain limited, and future studies should focus on phenotype-specific patient selection and optimized dosing strategies Clinicians should individualize therapy, weigh risks (especially Sphincter of Oddi effects), and integrate somatostatin analogue use into multidisciplinary management plans. [1–6, 11–16].  ?

 

 

REFERENCES

1. Pham A, et al. Chronic pancreatitis: review and update of etiology, risk factors and management. [Review]. 2018. 
2. Montorsi M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections. Br J Surg. 1995. 
3. Gurusamy KS, et al. Somatostatin analogues for pancreatic surgery — systematic review/meta-analysis. Cochrane/Br J Surg. 2013. 
4. Büchler MW, Uhl W. Role of octreotide and somatostatin in acute and chronic pancreatitis. Dig Surg. 1999/1994. 
5. Weckbecker G, et al. Octreotide mechanisms and clinical use. Ann Oncol. 2003. 
6. Luo L, Zhang H, Tang W, et al. Effect of octreotide acetate combined with somatostatin on treating acute pancreatitis and expression of miRNA-200 family. Int J Clin Exp Pathol. 2017. 
7. Sun C, et al. Current diagnosis and treatment of acute pancreatitis in China—role of somatostatin analogues. BMC Gastroenterol. 2021.  ?
8. Zheng H, et al. Systematic review/meta-analysis of prophylactic octreotide for complications after pancreatic resection. PLoS/PMC. 2019.  ?
9. Binmoeller KF, et al. Effect of somatostatin analogue octreotide on human sphincter of Oddi motility. Gastroenterology/Gut. 1992.  ?
10. Weber FH Jr., et al. Effect of octreotide on sphincter of Oddi motility. Scand J Gastroenterol. 1997.  ?
11. Lankisch PG, et al. Somatostatin analogues in pancreatitis — review. Digestion. 2002.  ?
12. García-Pesquera J, et al. Somatostatin in pancreatitis: mechanisms and clinical utility. World J Gastroenterol. 2021.  ?
13. Li J, et al. Somatostatin analogues for pancreatitis — Cochrane review (acute settings). 2013.  ?
14. Dlugosz A, et al. Short-term octreotide therapy in chronic pancreatitis: randomized trial. Scand J Gastroenterol. 1997.  ?
15. Lindkvist B, et al. Double-blind crossover trial of octreotide in chronic alcoholic pancreatitis. Pancreas. 2012.  ?
16. Mitchell RM, et al. Octreotide/somatostatin analogue therapy in CP — systematic review. Pancreatology. 2017.  ?
17. Büchler M, et al. Octreotide reduces complications after pancreatic surgery. Ann Surg. 1992.  ?
18. Pederzoli P, et al. Octreotide in pancreatic cancer surgery — impact on anastomotic leak/fistula. Pancreas. 1994.  ?
19. Yeo CJ, et al. Prophylactic octreotide after pancreaticoduodenectomy — prospective randomized trials and reviews. Review. 2000.  ?
20. Heider R, et al. Octreotide in pancreatic pseudocysts: clinical series. Pancreas. 2001.  ?
21. Connor S, et al. Meta-analysis of somatostatin analogues in pancreatic surgery. Br J Surg. 2005.  ?
22. Xiao L, et al. Sphincter of Oddi dysfunction and somatostatin analogues — review. Pancreatology. 2020.  ?
23. Telford JJ, et al. Pancreatic fistula outcomes with octreotide. Gastrointest Endosc. 2002.  ?
24. Ramos-De la Medina A, Sarr MG. Somatostatin analogues in prevention of pancreas-related complications after pancreatic resection. J Hepatobiliary Pancreat Surg. 2006.  ?
25. Wang C, et al. Systematic review: prophylactic octreotide use after pancreatic surgery — controversy & evidence. Medicine (Baltimore). 2017.  ?
26. Mao X, et al. Real-world usage of somatostatin and analogues in acute pancreatitis (Chinese database). APM. 2021.  ?
27. Li J, et al. Experimental data: octreotide attenuates severe acute pancreatitis in animal models. Gastroenterology/experimental studies. 1999–2025.  ?
28. Sun Y, et al. Combination therapy (octreotide + ulinastatin) in pancreatitis: meta-analyses in acute settings. Sci Rep / systematic reviews. 2022.  ?
29. Reubi JC. Somatostatin receptors in digestive disease and therapeutic implications. Gut. 2008.  ?
30. Frontiers: Sphincter of Oddi function and dysfunction — implications for therapy. Frontiers in Nutrition/Review. 2017.  ?